Literature DB >> 978809

Non-invasive papillary carcinoma of the bladder associated with carcinoma in situ.

A F Althausen, G R Prout, J J Daly.   

Abstract

We evaluated 129 patients with low grade, low stage transitional cell carcinoma of the bladder with a minimum followup of 5 years. In addition to the phenomena recognized as indicators of a serious clinical problem (grade greater than I, rapid recurrence, multiple tumors and lamina propria invasion) the identification of carcinoma in situ and/or atypia in normal, incidentally resected mucosa adjacent to the tumor was found to be a positive predictor for subsequent muscle invasion. Ten of 12 patients with carcinoma in situ and 9 of 25 patients with atypia were among 39 who experienced invasion.

Entities:  

Mesh：

Year:  1976        PMID： 978809     DOI： 10.1016/s0022-5347(17)58916-8

Source DB:  PubMed          Journal:  J Urol        ISSN： 0022-5347            Impact factor:   7.450


  40 in total

1.  Long-term BCG immune therapy of superficial bladder tumours.

Authors:  L Somogyi; A Szántó; L Polyák; F Baranyay; M Drinóczy
Journal:  Int Urol Nephrol       Date:  1992       Impact factor: 2.370

Review 2.  Chemoprevention of bladder cancer.

Authors:  Dragan J Golijanin; David Kakiashvili; Ralph R Madeb; Edward M Messing; Seth P Lerner
Journal:  World J Urol       Date:  2006-11       Impact factor: 4.226

3.  Early detection of urothelial premalignant lesions using hexaminolevulinate fluorescence cystoscopy in high risk patients.

Authors:  Salvatore Blanco; Marco Raber; Biagio Eugenio Leone; Luca Nespoli; Marco Grasso
Journal:  J Transl Med       Date:  2010-11-22       Impact factor: 5.531

4.  Analysis of tissue ABH antigens in superficial bladder tumours.

Authors:  H Tsujihashi; H Matsuda; S Uejima; T Akiyama; T Kurita
Journal:  Int Urol Nephrol       Date:  1991       Impact factor: 2.370

5.  Low-Grade, Multiple, Ta Non-muscle-Invasive Bladder Tumors: Tumor Recurrence and Worsening Progression.

Authors:  R B Nerli; Shridhar C Ghagane; K Shankar; Adarsh C Sanikop; Murigendra B Hiremath; Neeraj S Dixit; Laxman Magadum
Journal:  Indian J Surg Oncol       Date:  2018-01-29

Review 6.  Carcinoma in situ and treatment options.

Authors:  M Erton; Y Ilker
Journal:  Int Urol Nephrol       Date:  1996       Impact factor: 2.370

Review 7.  Epidermal growth factor receptor and bladder cancer.

Authors:  A J Colquhoun; J K Mellon
Journal:  Postgrad Med J       Date:  2002-10       Impact factor: 2.401

8.  Cystatin B as a tissue and urinary biomarker of bladder cancer recurrence and disease progression.

Authors:  Adam S Feldman; Jacqueline Banyard; Chin-Lee Wu; W Scott McDougal; Bruce R Zetter
Journal:  Clin Cancer Res       Date:  2009-02-01       Impact factor: 12.531

Review 9.  Superficial bladder carcinoma. Factors affecting the natural history.

Authors:  J M Fitzpatrick
Journal:  World J Urol       Date:  1993       Impact factor: 4.226

10.  Stem cell marker-positive stellate cells and mast cells are reduced in benign-appearing bladder tissue in patients with urothelial carcinoma.

Authors:  Björn L Isfoss; Christer Busch; Helena Hermelin; Anette T Vermedal; Marianne Kile; Geir J Braathen; Bernard Majak; Aasmund Berner
Journal:  Virchows Arch       Date:  2014-02-26       Impact factor: 4.064
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.